Successful management of severe refractory acquired immune bleeding disorder: Prior to insisting surgery  by Al-Jafar, Hassan et al.
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INTRODUCTION:  Acquired  bleeding  disorders  are rare  and  may  be  missed  before  surgery.  Additionally,
they  may  be refractory  to conventional  treatments.
PRESENTATION  OF  CASE:  A  50-year-old  patient  experienced  prolonged  post-operative  bleeding  when  his
bleeding  disorder  was  missed  prior  to  his  undergoing  inguinal  herniorrhaphy.  Post-operative  investiga-
tions  revealed  severe  acquired  von  Willebrand  syndrome  associated  with  a monoclonal  gammopathy
of undetermined  signiﬁcance.  A few  months  later,  he  required  umbilical  herniorrhaphy,  but  he  did  not
respond  to  attempts  to raise  his von  Willebrand  factor  antigen  and  activity  levels  using  conventional
therapies,  including  desmopressin,  cryoprecipitate,  intravenous  immunoglobulin,  and  Von  Willebrand
factor  concentrate.  A triple  therapy  combination  of  dexamethasone,  intravenous  immunoglobulin,  and
mycophenolate  mofetil  was administered,  with  a  successful  and  sustained  response,  lasting  about  2
months.  The  surgery  was  performed  safely,  without  any  complications.
DISCUSSION:  Conventional  acquired  von  Willebrand  syndrome  treatment  is usually  aimed  at replacing
von  Willebrand  factor  or stimulating  its secretion  from  storage  in endothelial  cells.  In  the  present  case,  the
alternative  treatment  was  directed  against  both  the  humoral  and  cell-mediated  immune  mechanisms.
CONCLUSION:  This  case  of acquired  bleeding  disorder  showed  that more  attention  must  be  given to  a
patient’s  coagulation  proﬁle,  even  if only  very  minor  laboratory  coagulation  derangements  are  detected
prior  to surgery,  to avoid  missing  such  rare  disorders.  The  described  triple  therapy  demonstrated  good
effects and may  be considered  for inclusion  in a controlled  randomized  study  to determine  its  usefulness
for  other  surgeries  delayed  due  to  severe  acquired  bleeding  disorders.  To  the  best  of our knowledge,  this
triple combination  treatment  has  not  been  previously  used  for the  treatment  of  severe  acquired  bleeding
disorders  that  are  refractory  to  conventional  therapies.
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. BackgroundSurgical procedures may  be postponed because of a high risk
f bleeding due to severe acquired bleeding disorders. One such
isorder is acquired von Willebrand syndrome (aVWS), a rare
Abbreviations: APTT, activated partial thromboplastin time; VWF  Ag, von Wille-
rand factor antigen; VWF  Act, von Willebrand factor activity; IgG, immunoglobulin
; aVWS, acquired von Willebrand syndrome; VWF, von Willebrand factor;
GUS, monoclonal gammopathy of undetermined signiﬁcance; MMF,  mycopheno-
ate mofetil; DIM, dexamethasone, intravenous immunoglobulin, mycophenolate
ofetil; VWD, von Willebrand disease.
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disorder that usually occurs in elderly patients, the recognition
of which may  be signiﬁcantly delayed.1 aVWS occurs due to
decreased levels of von Willebrand factor (VWF) antigen (VWF
Ag), and VWF  activity (VWF Act).2 These patients usually present
with mucocutaneous bleeding, in the absence of a previous his-
tory of bleeding abnormalities, and no clinically signiﬁcant family
history of bleeding disorders; they may  also be easily missed
prior to surgery because of demonstrating only minor labora-
tory coagulation derangement.3 However, such patients may  also
present with serious hemorrhagic complications that are challeng-
ing to manage,4 becoming more serious when the patient needs
surgery. aVWS may  be associated with lymphoproliferative dis-
orders, myeloproliferative neoplasms, solid tumors, autoimmune
disorders, and cardiovascular problems,5 and is characterized by
VWF  structural or functional abnormalities. In the lymphopro-
liferative monoclonal gammopathy of undetermined signiﬁcance
s Ltd. This is an open access article under the CC BY-NC-SA license
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MGUS) may  result in antibodies being directed against VWF,
esulting in its rapid inactivation or clearance from circulation;
WF  might also be absorbed from the plasma by malignant cells.6
he treatment of aVWS is normally directed against the under-
ying causes to enable remission.7 The conventional treatment
ethods usually involve administration of desmopressin (DDVAP),
ryoprecipitate, VWF  concentrate, and intravenous immunoglob-
lin (IVIG).8 In the present case, the patient failed to achieve a
ood response to the conventional therapies necessitating an alter-
ative therapeutic approach with dexamethasone, intravenous
mmunoglobulin, and mycophenolate mofetil (DIM) to enable the
atient to undergo required surgery.
. Presentation of case
A 50-year-old man  underwent elective, right inguinal hernior-
haphy in April 2009, complicated by prolonged bleeding from
he wound site. This necessitated hospital readmission for surgi-
al exploration of the wound and treatment with cryoprecipitate
nd vitamin K. The bleeding gradually resolved and, after 2 weeks
f hospitalization, he was discharged and referred to a hematology
linic. The laboratory results revealed a prolonged bleeding time
f 5.30 (normal, 1–4) minutes, an activated partial thromboplastin
ime (APTT) of 62 (normal, 33–39) second, an APTT mixing study
f 55 s, a factor VIII level of 7.22% (reference, 50–150%) of the nor-
al, a VWF  Ag of 7% (reference, 61–158%) of the normal, a VWF
ct of 27% (reference, 38.1–152.2%) of the normal, and a normal
nternational normalized ratio (INR); other coagulation factors, and
enal and liver functions were also normal. The patient had not
reviously experienced signiﬁcant bleeding symptoms, including
n 1998 when he underwent multiple dental extractions without
ndue blood loss. The patient did not have a family history of bleed-
ng disorders; his parents were not consanguineous and none of
is 7 siblings or 4 children exhibited any bleeding tendency. Apart
rom hypertension, for which he was taking amlodipine (10 mg,
nce daily), he did not have a remarkable medical history.
able 1
omparison of the effect of three lines of treatment on the patient.
Treatment Day APTT FVIII
(% of normal)
V
(
1. I & VWF  con BL1 1 29 0.08 0
2.  D & I BL2 1 36 15 0
4  27 89 2
6  26 150 9
10 24 221 1
20 26 81 5
3.  DIM BL3 1 ND 66 3
2  26 110 5
3  ND 78 5
9  27 221 2
21 23 258 3
28 24 ND 2
MMF  reduction to 1000 mg  30 ND 130 1
MMF  discontinuation 60 32 36 1
No  treatment 360 34 36 1
Normal ranges 26–37 50–150 6
L1: Base line just before I & VWF  con treatment.
L2: Base line just before D & I treatment.
L3: Base line just before DIM treatment.
PTT: activated partial thromboplastin time.
VIII: factor VIII.
WF  Ag: von Willebrand factor antigen.
WF  Act: von Willebrand factor activity.
WF  Con: VWF: concentrate.
: dexamethasone.
: immunoglobulin G.
MF: mycophenolate mofetil.
D = not done.PEN  ACCESS
gery Case Reports 5 (2014) 1186–1189 1187
In June 2011, the patient was scheduled for umbilical hernior-
rhaphy surgery. Prior to surgery, repeat testing conﬁrmed von
Willebrand disease; the patient again demonstrated signiﬁ-
cantly reduced levels of factor VIII 0.08 (normal, 0.45–1.8 U/mL)
and VWF  Ag 0.11 (normal, 0.5–2.00 U/mL). The Platelet Func-
tion Analyzer-100 closure time was extended beyond 300 s for
the collagen/epinephrine-coated membrane (normal, 75–165 s);
serum protein electrophoresis revealed monoclonal immunoglob-
ulin G (IgG)-lambda paraprotein levels of 8 (normal, 7.5–18) g/L
and beta-2-microglobulin levels of 1.38 (normal, 1–2.20) g/L. As
a result, the patient was  diagnosed with aVWS associated with
MGUS. The low level of VWF  was conﬁrmed to be due to accel-
erated clearance of VWF; the administration of a test dose of VWF
concentrate resulted in its rapid disappearance from circulation.
Prior to surgery, the patient was  administered VWF  concentrate
and IVIG (1 g/kg/day) for 1 day, to restore his VWF  function dur-
ing surgery, producing a signiﬁcant rise in VWF  and factor VIII
levels. An additional dose of VWF  concentrate was administered
the next day in anticipation that the VWF  levels would improve
sufﬁciently to allow the surgery to proceed. However, the surgery
could not be performed because the rise in his VWF  level was
insufﬁcient. The patient returned to our hospital after 45 days.
Serum immunoglobulin electrophoresis and immune ﬁxation tests
done which demonstrated monoclonal lambda-type IgG (30.1 g/L;
normal, 7.5–18.0 g/L), IgA (3.76 g/L; normal, 0.9–4.5 g/L), and IgM
(1.03 g/L; normal, 0.6–2.5 g/L). Bence–Jones proteins and bone lytic
lesions were not detected in this patient. The patient’s coagulation
proﬁle had a normal INR of 0.09 and an APTT of 29 (normal, 33–39)
second.
In March 2012, the patient was again scheduled for surgery, after
it had been postponed several times over the previous 3 years,
because of the high risk of bleeding. The patient was  prescribed
oral dexamethasone (40 mg/day) and omeprazole (20 mg/day) for
4 days, together with IVIG (0.4 mg/kg) for 5 days; however, the
surgery was postponed by the patient. The treatment effect on VWF
Ag, and VWF  Act lasted only for 10 days. When the treatment was
attempted again, mycophenolate mofetil (MMF,  1000 mg,  twice
WF  Ag
% of normal)
VWF  Act
(% of normal)
IgG
(g/L)
Note
.11 ND 30 Not effective
 0 15.1 Short Effective
9 51 ND
5 108 ND
47 146 ND
1 38 ND
0 15 ND Longer sustained
Effective for6 38 ND
6 39 17.9
40 151 ND
30 210 ND
44 144 ND
01 70 ND Back to base line when
MMF  stopped8 14 ND
8 0 12.7
1–158 38.1–152.2 7.5–18.0
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aily) was added to the previous drug regimen. DIM gave a pro-
onged and sustained effect lasted for about 2 months. The patient’s
WF  Ag, VWF  Act, and factor VIII levels fell after the MMF  dose was
educed to 500 mg  twice daily, and returned to the baseline level
fter discontinuing MMF  (Table 1).
. Discussion
The biosynthesis of VWF  is restricted to endothelial cells and
egakaryocytes, from which it is constitutively secreted into
he blood or subendothelial matrix. VWF  may  also be stored in
eibel–Palade bodies in endothelial cells, and released upon stim-
lation or via an unstimulated, but regulated, basal pathway.9 The
PTT, in patients with congenital or acquired Von Willebrand dis-
ase (VWD), is usually prolonged because of reduced levels of factor
III, which typically accompany a reduction in VWF  levels. How-
ver, a highly signiﬁcant ﬁnding in aVWS is the possibility of a
ormal or only slightly elevated APTT, which makes severe cases of
VWS easily missed prior to surgery. Hence, a bleeding time test is
 useful, easily available test to screen for the presence of aVWS.10
Conventional aVWS treatment is usually aimed at replacing
WF  or stimulating its secretion from storage in endothelial cells
hrough the administration of DDVAP, which increases plasma lev-
ls of factor VIII and VWF. DDVAP has been successfully used for
he treatment of the milder, congenital forms of hemophilia A and
WD. However, DDVAP is not uniformly effective in correcting the
bnormal hemostasis of aVWS patients. When DDVAP fails to cor-
ect VWF  Ag and VWF  Act, the usual treatment involves replacing
he VWF  levels, including the administration of cryoprecipitate,
WF concentrate, and IVIG when an autoimmune disorder is sus-
ected to be associated with aVWS.11
In the present case, the DIM treatment was directed against
oth the humoral and cell-mediated immune mechanisms by
irtue of dexamethasone having powerful anti-inﬂammatory
nd immunosuppressive effects,12 IVIG down-regulating antibody
roduction,13 and MMF  exerting immunosuppressive effects on
oth B and T lymphocytes.14 The patient had shown only a short,
artial response to treatment with IVIG and VWF  concentrate, and
he increases in VWF  Ag and VWF  Act levels were not sustained,
ither due to a high titer of the inhibitors to VWF  activity or because
f high grade interference with the VWF  antigen. When dexameth-
sone was added to the IVIG treatment, the combination was more
ffective at maintaining normal VWF  Ag and VWF  Act levels for
 days. When MMF  was further added, the VWF  Ag and VWF  Act
evels were maintained at an acceptable level for approximately 2
onths, sufﬁcient to allow complete wound healing. The VWF  Ag
nd Act returned to the pre-treatment, baseline level only when
MF  was discontinued.
In this case, the underlying immune cause was  treated by
mmunosuppressive drug therapy, rather than by replacing the
eﬁcient factors. DIM shoed a much more signiﬁcant response than
id rituximab when the latter was used to treat aVWS secondary to
n autoimmune antibody response.15 Replacing the deﬁcient factor
s more effective in patients with congenital VWD, but less so for
those with acquired bleeding disorders. In patients with acquired
immune factor deﬁciencies, replacing the deﬁcient factors makes
the immune disorder more refractory to treatment, similar to what
occurs in immune thrombocytopenia16 and immune hemolytic
anemia.17 In this case, the APTT was  not excessively prolonged,
then became within normal limits while the VWF  Ag and Act were
both very low. Additionally, the IgG level did not correlate with the
VWF  Ag and Act, which suggests the possibility of a speciﬁc pri-
mary autoimmune antibody directed against VWF, in association
with MGUS.
From this experience, both the coagulation proﬁle and bleed-
ing times are important parameters to be checked before surgical
procedures, even in the absence of a personal or family history of
bleeding disorders. Normal or minor impairments in a patient’s
coagulation proﬁle can hide a major, severe acquired disorder. DIM
was a more successful treatment for refractory aVWS than con-
ventional treatments, especially since surgery was required in a
high-risk aVWS patient. The suitability of DIM for other acquired
bleeding disorders should be investigated through randomized
controlled studies.
This patient leading normal life without hemostatic treatment
but for surgery he require DIM treatment to avoid catastrophic
bleeding because of his sever refractory aVWS. Dexamethason and
IVIG alone have only short effect and MMF  alone did not keep the
levels to normal so DIM combination has the best and more sustain
effect. This patient presentation is rare in the possibility of cata-
strophic hemorrhage during surgery and the presence of mild to
normal coagulation proﬁle derangement.
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Key learning points
• Mild INR or APTT could have serious underling coagulation disorder.
• Bleeding time is important prior to surgery in cases of deranged coagulopathy.
• The combination of dexamethasone, intravenous immunoglobulin, and mycophenolate mofetil could be useful inacquired cases of coagulopathy requiring insisting surgery w
based, more clinical trails required to prove he efﬁcacy of thihen the underling cause of coagulopathy is an immune
s combination.
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